PT3496743T - Composições e métodos para o tratamento do cancro com depleção de arginina e agentes imuno-oncológicos - Google Patents

Composições e métodos para o tratamento do cancro com depleção de arginina e agentes imuno-oncológicos

Info

Publication number
PT3496743T
PT3496743T PT178404208T PT17840420T PT3496743T PT 3496743 T PT3496743 T PT 3496743T PT 178404208 T PT178404208 T PT 178404208T PT 17840420 T PT17840420 T PT 17840420T PT 3496743 T PT3496743 T PT 3496743T
Authority
PT
Portugal
Prior art keywords
compositions
methods
treating cancer
oncology agents
arginine depletion
Prior art date
Application number
PT178404208T
Other languages
English (en)
Original Assignee
Aerase Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerase Inc filed Critical Aerase Inc
Publication of PT3496743T publication Critical patent/PT3496743T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001Arginase (3.5.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT178404208T 2016-08-08 2017-09-08 Composições e métodos para o tratamento do cancro com depleção de arginina e agentes imuno-oncológicos PT3496743T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662372092P 2016-08-08 2016-08-08
US201762524286P 2017-06-23 2017-06-23

Publications (1)

Publication Number Publication Date
PT3496743T true PT3496743T (pt) 2022-03-30

Family

ID=61163268

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178404208T PT3496743T (pt) 2016-08-08 2017-09-08 Composições e métodos para o tratamento do cancro com depleção de arginina e agentes imuno-oncológicos

Country Status (18)

Country Link
US (2) US10729752B2 (pt)
EP (1) EP3496743B1 (pt)
AU (1) AU2017310541B2 (pt)
BR (1) BR112019002458A2 (pt)
CY (1) CY1125158T1 (pt)
DK (1) DK3496743T3 (pt)
ES (1) ES2909556T3 (pt)
GB (1) GB2568000A (pt)
HR (1) HRP20220406T1 (pt)
HU (1) HUE057901T2 (pt)
IL (1) IL264535B (pt)
LT (1) LT3496743T (pt)
PL (1) PL3496743T3 (pt)
PT (1) PT3496743T (pt)
RS (1) RS63075B1 (pt)
RU (1) RU2771313C2 (pt)
SI (1) SI3496743T1 (pt)
WO (1) WO2018032020A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909556T3 (es) 2016-08-08 2022-05-09 Aerase Inc Composiciones y procedimientos para el tratamiento de cáncer con agentes de disminución de arginina y de inmunoncología
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
TWI726426B (zh) * 2018-09-25 2021-05-01 大陸商信達生物製藥(蘇州)有限公司 包含抗ox40抗體的製劑、其製備方法及其用途
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
CA3149592A1 (en) * 2019-08-30 2021-03-04 Scott W. Rowlinson Methods for production of human recombinant arginase 1 and uses thereof
WO2022195629A1 (en) * 2021-03-18 2022-09-22 National Institute Of Pharmaceutical Education And Research (Niper) Engineered arginase constructs, method of generation and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02117383A (ja) 1988-10-26 1990-05-01 Tosoh Corp ヒトアルギナーゼの製造方法
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
WO2003063780A2 (en) 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
CN1745847A (zh) 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
WO2007070392A2 (en) 2005-12-12 2007-06-21 Canji, Inc. Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
FI3778885T3 (fi) 2008-10-31 2023-05-23 Aerase Inc Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
US8679479B2 (en) * 2009-06-29 2014-03-25 Aerase, Inc. Methods for purifying pegylated arginase
WO2012061015A2 (en) * 2010-11-03 2012-05-10 Scott & White Healthcare L-citrulline supplementation during arginine depletion therapy with arginase
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
MX2016010285A (es) 2014-02-11 2017-01-11 Univ Colorado Regents Ingenieria genetica multiplexada habilitada por crispr.
WO2015164743A2 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
HUE043847T2 (hu) * 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
EP3215850B1 (en) * 2014-11-03 2019-07-03 F. Hoffmann-La Roche AG Assays for detecting t cell immune subsets and methods of use thereof
WO2017050240A1 (en) * 2015-09-21 2017-03-30 Bio-Cancer Treatment International Ltd. Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
ES2909556T3 (es) 2016-08-08 2022-05-09 Aerase Inc Composiciones y procedimientos para el tratamiento de cáncer con agentes de disminución de arginina y de inmunoncología

Also Published As

Publication number Publication date
IL264535A (en) 2019-02-28
RU2771313C2 (ru) 2022-04-29
WO2018032020A1 (en) 2018-02-15
US20200360493A1 (en) 2020-11-19
GB2568000A (en) 2019-05-01
AU2017310541A1 (en) 2019-03-07
ES2909556T3 (es) 2022-05-09
CY1125158T1 (el) 2024-02-16
EP3496743A1 (en) 2019-06-19
US10729752B2 (en) 2020-08-04
PL3496743T3 (pl) 2022-05-30
SI3496743T1 (sl) 2022-08-31
RU2019106501A (ru) 2020-09-14
EP3496743B1 (en) 2022-02-09
HRP20220406T1 (hr) 2022-05-27
AU2017310541B2 (en) 2024-06-13
BR112019002458A2 (pt) 2019-05-14
DK3496743T3 (da) 2022-04-04
US20180177853A1 (en) 2018-06-28
EP3496743A4 (en) 2020-03-18
HUE057901T2 (hu) 2022-06-28
GB201903065D0 (en) 2019-04-24
IL264535B (en) 2022-01-01
RU2019106501A3 (pt) 2021-01-15
LT3496743T (lt) 2022-04-11
RS63075B1 (sr) 2022-04-29

Similar Documents

Publication Publication Date Title
IL267247B (en) Compositions and methods for treating cancer
EP3507304C0 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DUOCARS
ZA202006627B (en) Methods and compositions for treating cancer
IL269150A (en) Preparations and methods for the treatment of cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
IL263224A (en) Methods and preparations for the treatment of cancer
IL304820A (en) Preparations and methods for the treatment of cancer
IL264535B (en) Preparations and methods for treating cancer using arginine reduction and immuno-oncological agents
PT3377516T (pt) Composição para o tratamento do cancro
IL265786A (en) Materials and methods for increasing radiotherapy against cancer
IL269157A (en) Preparations and methods for the treatment of cancer
IL274837A (en) Methods and preparations for the treatment of cancer
IL271326A (en) Compositions and methods for enhancing radiotherapy in cancer
IL257274B (en) Preparations and methods for the treatment of cancers related to the activation of the endothelin B receptor.
IL256523A (en) Compositions and methods for treating cancer
SG11202012435UA (en) Compositions and methods for treating cancer
EP3681903C0 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19 IMMUNOTHERAPY
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL261146A (en) Methods and compounds for the treatment of cancerous tumors and malignancies
EP3697426C0 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD22 IMMUNOTHERAPY
IL255638A (en) Compositions and methods for treating cancer
IL272782A (en) Preparations and methods for the treatment of cancer
SG11202002123XA (en) Compositions and methods for treating liver cancer
ZA201802268B (en) Methods and compositions for preventing or treating cancer
IL282948A (en) Preparations and methods for the treatment of cancer